Once-weekly
Aged
Aged, 80 and over
Antineoplastic Agents
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Drug Administration Schedule
Female
Humans
Induction Chemotherapy
Maintenance Chemotherapy
Male
Middle Aged
Multiple Myeloma
/ diagnosis
Oligopeptides
/ administration & dosage
Prognosis
Survival Analysis
Treatment Outcome
Journal
Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
04
10
2018
accepted:
07
02
2019
pubmed:
9
2
2019
medline:
17
6
2020
entrez:
9
2
2019
Statut:
ppublish
Résumé
Twice-weekly carfilzomib is approved at 27 and 56 mg/m
Identifiants
pubmed: 30733270
pii: haematol.2018.208272
doi: 10.3324/haematol.2018.208272
pmc: PMC6669142
doi:
Substances chimiques
Antineoplastic Agents
0
Oligopeptides
0
carfilzomib
72X6E3J5AR
Banques de données
ClinicalTrials.gov
['NCT01346787']
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1640-1647Informations de copyright
Copyright© 2019 Ferrata Storti Foundation.
Références
Blood. 2010 Dec 2;116(23):4745-53
pubmed: 20807892
Blood. 2012 Aug 30;120(9):1801-9
pubmed: 22665938
J Clin Oncol. 2013 Feb 1;31(4):448-55
pubmed: 23233713
Leukemia. 2014 May;28(5):1122-8
pubmed: 24157580
Blood. 2014 Jul 3;124(1):63-9
pubmed: 24855212
Haematologica. 2014 Sep;99(9):e162-4
pubmed: 24972772
Blood. 2015 Jan 15;125(3):449-56
pubmed: 25398935
N Engl J Med. 2015 Jan 8;372(2):142-52
pubmed: 25482145
Blood. 2015 Mar 26;125(13):2068-74
pubmed: 25628469
Lancet Oncol. 2016 Jan;17(1):27-38
pubmed: 26671818
Blood. 2016 Jun 16;127(24):2955-62
pubmed: 27002115
Blood. 2016 Jun 30;127(26):3360-8
pubmed: 27207788
Leukemia. 2017 Jun;31(6):1368-1374
pubmed: 28025582
Clin Lymphoma Myeloma Leuk. 2017 Jul;17(7):433-437
pubmed: 28576443
Lancet Oncol. 2017 Oct;18(10):1327-1337
pubmed: 28843768
Leukemia. 2018 Apr;32(4):979-985
pubmed: 29263440
Lancet Oncol. 2018 Jul;19(7):953-964
pubmed: 29866475